Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987710 | 1.00 | MTNR1A (0.57) | MTNR1AMTNR1BPDPK1HTTTAS1R3 | |
| SCHEMBL606392 | 0.91 | HTT (0.63) | HTTTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL15006999 | 0.91 | HTT (0.63) | HTTTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL1266129 | 0.91 | HTT (0.63) | HTTTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL18701560 | 0.84 | PDPK1 (0.56) | PDPK1HTTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL19969316 | 0.81 | PDPK1 (0.51) | PDPK1HTTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1265290 | 0.81 | LMNA (0.47) | MTNR1AMTNR1BHTTEPHX2ALDH1A1 | |
| SCHEMBL15006926 | 0.81 | LMNA (0.47) | MTNR1AMTNR1BHTTEPHX2ALDH1A1 | |
| SCHEMBL31277918 | 0.81 | PDE10A (0.47) | MTNR1AMTNR1BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1265292 | 0.81 | LMNA (0.47) | MTNR1AMTNR1BHTTEPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0738149-B1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 2006-11-29 | — | — | EP | claimed |
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | COHEN SASSON (IL) | 2002-06-06 | — | — | US | claimed |
| US-5994408-A | THERAPY FOR PARKINSON'S DISEASE; ANTICONVULSANT | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-11-30 | — | — | US | claimed |
| EP-2939669-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2015-11-04 | — | — | EP | disclosed |
| EP-2663545-B1 | A NEW METHOD FOR THE SYNTHESIS OF RASAGILINE | NOBEL ILAÇ SANAYII VE TICARET A S (TR) | 2015-07-01 | — | — | EP | disclosed |
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | KANDULA MAHESH (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | KANDULA MAHESH (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150045445-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2015-02-12 | — | — | US | disclosed |
| US-8901352-B2 | Method for the synthesis of rasagiline | NOBEL ILAÇ SANAYII VE TICARET A.S. (TR) | 2014-12-02 | — | — | US | disclosed |
| US-8901352-B2 | Method for the synthesis of rasagiline | NOBEL ILAÇ SANAYII VE TICARET A.S. (TR) | 2014-12-02 | — | — | US | disclosed |
| EP-1592674-B1 | AMINO 1, 3, 5-TRIAZINES N-SUBSTITUTED WITH CHIRAL BICYCLIC RADICALS, PROCESS FOR THEIR PREPARATION, COMPOSITIONS THEREOF AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2014-03-05 | — | — | EP | disclosed |
| US-5880159-A | TREATING ACUTE NEUROLOGICAL TRAUMATIC DISORDER OR NEUROTRAUMA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-09 | — | — | US | disclosed |
| US-5877221-A | TREATING DEMENTIA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | disclosed |
| US-5877218-A | PARKINSON'S DISEASE; ANTIEPILEPSY AGENTS; ANTICONVULSANTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | disclosed |
| WO-1998027055-A1 | AMINOINDAN DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1998-06-25 | — | — | WO | disclosed |
| US-5639913-A | TREATMENT OF PARKINSON'S DISEASE, DEMENTIA, EPILEPSY | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-06-17 | — | — | US | disclosed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996021454-A1 | PHOSPHATE-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX PHARMACEUTICALS, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| WO-1996021640-A1 | OPTICALLY ACTIVE AMINOINDANE DERIVATIVES AND PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-07-18 | — | — | WO | disclosed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045445-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | PKD1, NAT1, AAAS | MTNR1A 1721/4885MTNR1B 2699/4885PDPK1 1438/4885 |
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | HTT, SNCA, PARK7 | MTNR1A 228/4885MTNR1B 370/4885PDPK1 2940/4885 |
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | PARK7, GAP43, PSEN1 | MTNR1A 135/4885MTNR1B 374/4885PDPK1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.